Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study-Reference-Cited by-同舟云学术

Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study

Published:2017-04 Issue:4 Volume:18 Page:446-453
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Morris Van K,Salem Mohamed E,Nimeiri Halla,Iqbal Syma,Singh Preet,Ciombor Kristen,Polite Blase,Deming Dustin,Chan Emily,Wade James L,Xiao Lianchun,Bekaii-Saab Tanios,Vence Luis,Blando Jorge,Mahvash Armeen,Foo Wai Chin,Ohaji Chimela,Pasia Manolo,Bland Gail,Ohinata Aki,Rogers Jane,Mehdizadeh Amir,Banks Kimberly,Lanman Richard,Wolff Robert A,Streicher Howard,Allison James,Sharma Padmanee,Eng Cathy

Publisher

Elsevier BV

Subject

Oncology

Reference35 articles.

1. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis;de Martel;Lancet Oncol,2012

2. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups.

3. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study;Flam;J Clin Oncol,1996

4. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer;Das;Int J Radiat Oncol Biol Phys,2007

5. Anal cancer: current and future methodology;Eng;Cancer Invest,2006

Cited by 327 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy in gastrointestinal cancers: Spotlight on the pivotal role of currently available biomarkers;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025

2. Management of Metastatic Anal Cancer;Surgical Oncology Clinics of North America;2024-09

3. Recent developments in immunotherapy for gastrointestinal tract cancers;Journal of Hematology & Oncology;2024-08-09

4. The Efficacy and Safety of Pembrolizumab, Ipilimumab, and Nivolumab Monoteraphy and Combination for Colorectal Cancer: A Systematic Review and Meta-Analysis;2024-07-03

5. Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort;Journal for ImmunoTherapy of Cancer;2024-07